Last Updated: November 16, 2026

Investigational Drug Information for Edivoxetine

« Back to Dashboard


What is the development status for investigational drug Edivoxetine?

Edivoxetine is an investigational drug.

There have been 11 clinical trials for Edivoxetine. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].

Recent Clinical Trials for Edivoxetine
TitleSponsorPhase
A Study of LY2216684 in Participants With Major Depression DisorderEli Lilly and CompanyPhase 3
A Study of LY2216684 in Healthy ParticipantsEli Lilly and CompanyPhase 1
A Study in Prevention of Re-emergence of Depression SymptomsEli Lilly and CompanyPhase 3

See all Edivoxetine clinical trials

Clinical Trial Summary for Edivoxetine

Top disease conditions for Edivoxetine
Top clinical trial sponsors for Edivoxetine

See all Edivoxetine clinical trials

Last updated: September 9, 2026

Edivoxetine is a discontinued Eli Lilly investigational drug candidate. The selective norepinephrine reuptake inhibitor reached Phase 3 development as adjunctive therapy for major depressive disorder but failed to meet key efficacy objectives. Lilly subsequently ended development. Edivoxetine has no FDA approval, no Orange Book listing, no commercial sales, and no credible near-term market forecast. Its base-case commercial value is zero unless a sponsor restarts development or acquires the program.

Edivoxetine Development Update and Market Projection

What is the current development status of edivoxetine?

Edivoxetine, also known as LY2216684, is an investigational selective norepinephrine reuptake inhibitor developed by Eli Lilly and Company. Lilly studied the compound primarily as an adjunct to an existing selective serotonin reuptake inhibitor in adults with major depressive disorder who had an inadequate response to antidepressant treatment.

The program advanced into Phase 3 clinical testing. Public trial records identify multiple studies evaluating edivoxetine as adjunctive treatment for major depressive disorder. The development program did not establish sufficient efficacy for regulatory submission, and Lilly discontinued further development.

Field Edivoxetine status
Generic name Edivoxetine
Lilly code LY2216684
Drug class Selective norepinephrine reuptake inhibitor
Primary development area Major depressive disorder
Development strategy Adjunctive treatment with an SSRI
Highest public development stage Phase 3
Sponsor Eli Lilly and Company
FDA approval None
Commercial launch None
Current marketed product None
Development status Discontinued

ClinicalTrials.gov records describe edivoxetine studies in patients with major depressive disorder who had an inadequate response to SSRI therapy. The studies were completed rather than converted into a regulatory filing or commercial launch (National Library of Medicine, 2024).

Why was edivoxetine development discontinued?

Edivoxetine development was discontinued after Phase 3 results failed to demonstrate the required benefit over placebo on the primary efficacy measures used in the major depressive disorder program. Lilly disclosed the discontinuation in its corporate reporting and pipeline updates.

The commercial and regulatory problem was clear:

  1. Edivoxetine did not produce a sufficiently reliable efficacy advantage in the studied adjunctive population.
  2. The compound would have entered a crowded antidepressant market with established generic SSRIs and SNRIs.
  3. An adjunctive product would have required prescribers to add a second branded therapy to an existing treatment regimen.
  4. The program did not generate a sufficiently strong benefit-risk or differentiation profile to justify further investment.

The discontinuation appears to have been a program-level decision rather than a temporary clinical hold. No subsequent Lilly announcement has established a restarted Phase 3 program, a regulatory resubmission, or a licensing transaction for edivoxetine.

What FDA regulatory status does edivoxetine have?

Edivoxetine has no FDA approval and no publicly identified New Drug Application approval history. It is not an FDA-approved active ingredient, finished dosage form, or antidepressant product.

The FDA regulatory position is therefore:

Regulatory category Status
Investigational New Drug program Historical
New Drug Application No approval identified
FDA label None
Risk Evaluation and Mitigation Strategy None identified
Pediatric exclusivity None identified
Orphan-drug designation None identified
New chemical entity exclusivity Not commercially used
Approved indication None

The absence of approval eliminates the conventional launch sequence involving FDA review, labeling negotiations, controlled distribution, and postmarketing commitments.

What is the Orange Book status of edivoxetine?

Edivoxetine has no Orange Book-listed product because no edivoxetine product received FDA approval. The Orange Book lists approved drug products and associated patent and exclusivity information. An investigational compound that never reaches approval does not obtain an Orange Book commercial listing (U.S. Food and Drug Administration, 2024).

This has several consequences:

  • There is no Orange Book patent certification pathway for generic applicants.
  • No Paragraph IV litigation is associated with an approved edivoxetine product.
  • No 30-month stay could arise from an edivoxetine ANDA challenge.
  • No listed drug exists against which a generic applicant could file an ANDA.
  • Any future developer would need to establish its own regulatory pathway.

Are there Paragraph IV challenges or patent litigation involving edivoxetine?

No meaningful Paragraph IV challenge or commercial patent litigation is associated with edivoxetine because the compound never became an approved reference product.

Historical development patents may have covered the active compound, pharmaceutical compositions, or methods of treatment. Those rights do not create a commercial barrier comparable to an active Orange Book estate. A patent can remain legally relevant after clinical discontinuation, but its practical value depends on remaining term, claim scope, enforceability, ownership, and the existence of a commercial product.

No public settlement agreement involving an ANDA challenger, authorized generic, or branded edivoxetine launch has been established. No public patent settlement appears to have affected the commercial timing of edivoxetine.

What formulations and methods of use were protected?

The clinical program used oral edivoxetine in an adjunctive antidepressant setting. Public development information supports the following broad technical categories:

Potential protection category Relevance to edivoxetine
Active compound claims Could cover edivoxetine or related chemical matter
Oral pharmaceutical compositions Could cover tablets or other oral dosage forms
Combination therapy claims Could cover use with SSRIs
Method-of-use claims Could cover treatment of major depressive disorder
Manufacturing claims Could cover synthesis, intermediates, or purification
Extended-release formulations No commercial product or approved formulation established

The most commercially relevant proposed use was adjunctive treatment of major depressive disorder in patients with inadequate response to SSRI therapy. Because Lilly did not launch an approved product, formulation and method-of-use rights did not produce a market-access barrier.

An exhaustive patent-expiration analysis cannot be inferred from clinical-trial records alone. Patent term would vary by family, filing date, issued claims, terminal disclaimers, patent-term adjustment, and any patent-term extension. No approved product means there is also no FDA-linked patent listing that can be used as a definitive commercial exclusivity schedule.

When did edivoxetine lose exclusivity?

Edivoxetine did not lose market exclusivity through generic entry. It never obtained an approved commercial exclusivity period.

The relevant timeline is:

Event Timing or status
Discovery and preclinical development Historical Lilly program
Phase 2 and Phase 3 clinical testing Completed
Phase 3 efficacy failure Historical
Development discontinuation Historical, following Phase 3 results
FDA approval Never obtained
Commercial launch Never occurred
Generic entry Not applicable
Current market exclusivity None

Any underlying composition-of-matter patents may have expired or may have had residual term depending on the individual patent family. That distinction has limited commercial importance without an approved product or active development sponsor.

What is the market projection for edivoxetine?

The base-case market projection is zero revenue through the foreseeable forecast period. Edivoxetine has no approved indication, no marketed formulation, no active branded sales, and no identified regulatory filing that would support a launch forecast.

Forecast scenario Probability assessment Commercial outcome
No restart of development Highest-probability scenario $0 product revenue
Licensing to another sponsor Low Dependent on new clinical and regulatory investment
Restart from prior clinical data Low Several years before possible approval
New indication development Very low Requires a new clinical strategy and additional trials
Generic or follow-on launch Not applicable No approved reference product

A restart would require more than a transaction. A sponsor would need to review the complete clinical data package, confirm manufacturing readiness, assess intellectual-property rights, establish a regulatory strategy, and determine whether the failed efficacy signal can be overcome in a narrower population or different combination regimen.

The likely development timeline for a restart would be material. Even if prior Phase 3 data were considered usable, the sponsor would probably need additional clinical work before filing. A practical path from reactivation to potential approval would likely extend several years, with high execution and clinical risk.

How large was the potential market for adjunctive edivoxetine?

The theoretical market was the population of adults with major depressive disorder who did not respond adequately to SSRI treatment. That population is substantial, but the addressable market for edivoxetine would have been much smaller than the total antidepressant market.

Commercial constraints would have included:

  • Competition from generic SNRIs such as venlafaxine and duloxetine.
  • Competition from approved adjunctive therapies, including atypical antipsychotics.
  • Physician preference for established augmentation strategies.
  • Payer pressure against a branded add-on product.
  • Need for demonstrated incremental benefit over low-cost generic options.
  • Potential tolerability concerns associated with noradrenergic activity, including cardiovascular and activating effects.

Edivoxetine would have required a clinically meaningful differentiation claim. A modest improvement over placebo would likely not have been sufficient to support premium pricing in an adjunctive market dominated by established therapies.

How does edivoxetine compare with competing antidepressant products?

Product or class Regulatory status Market position relative to edivoxetine
Generic SSRIs Approved and widely used Established first-line competitors
Generic SNRIs Approved and widely used Compete through both serotonin and norepinephrine activity
Aripiprazole adjunctive therapy Approved for adjunctive MDD use Direct commercial competition in augmentation
Brexpiprazole adjunctive therapy Approved for adjunctive MDD use Direct branded competition
Bupropion Approved for depression and augmentation use Alternative mechanism and established prescribing base
Edivoxetine Unapproved No commercial position

Edivoxetine’s mechanism was not sufficiently differentiated by itself. Its commercial case depended on proving better efficacy, tolerability, speed of action, or patient selection than existing augmentation strategies.

What is the revenue exposure for Eli Lilly?

Edivoxetine did not generate material product revenue because Lilly never commercialized it. The financial exposure was development expenditure and opportunity cost rather than lost sales from generic competition.

The discontinuation also prevented Lilly from building a branded antidepressant franchise around edivoxetine. Any residual patent value would have depended on a third-party acquisition or a new clinical opportunity. No public transaction has established a meaningful valuation for the asset.

What is the patent strength of the edivoxetine estate?

The practical patent strength is weak from a commercial perspective. This assessment reflects the absence of an approved product and an active development program, not necessarily the invalidity of individual historical patents.

Patent-strength factor Assessment
Approved product supported by patents No
Orange Book-listed patents None
Active commercial sponsor Not identified
Paragraph IV exposure None
Composition-of-matter value Potentially historical
Formulation value Limited without a product
Method-of-use value Limited after program discontinuation
Manufacturing barrier Potentially relevant only after restart
Licensing value Speculative and dependent on clinical revival

What generic launch risks exist?

There is no conventional generic launch risk because no approved edivoxetine reference product exists. The more relevant risk is that a future sponsor could revive the compound or develop a related molecule, creating competition for any later entrant.

A future restart would face:

  • Clinical risk from the prior Phase 3 failure.
  • Regulatory risk from the absence of an approved precedent.
  • Patent-term risk if key composition claims have expired.
  • Formulation and manufacturing redevelopment costs.
  • Reimbursement risk in a genericized antidepressant market.
  • Competitive risk from newer augmentation products.

Key Takeaways

  • Edivoxetine is an Eli Lilly investigational selective norepinephrine reuptake inhibitor.
  • Its principal development program targeted adjunctive treatment of major depressive disorder.
  • The compound reached Phase 3 but failed to establish sufficient efficacy.
  • Lilly discontinued development after the Phase 3 program.
  • Edivoxetine has no FDA approval, label, Orange Book listing, or commercial sales.
  • No Paragraph IV challenge, ANDA litigation, or generic settlement is associated with the compound.
  • Historical patent rights may exist, but they do not create a current commercial exclusivity position.
  • The base-case market projection is zero revenue.
  • Any future value would depend on a new sponsor, a licensing transaction, and successful clinical redevelopment.

Frequently Asked Questions

Is edivoxetine still being developed?

No active public development program has been established. Lilly discontinued the program after unsuccessful Phase 3 testing in major depressive disorder.

Was edivoxetine approved for depression?

No. The FDA has not approved edivoxetine for major depressive disorder or any other indication.

Can a generic version of edivoxetine be launched?

No conventional generic pathway exists because edivoxetine has no approved reference product. A future sponsor would need to obtain approval before an ANDA-based generic market could arise.

Did edivoxetine have an antidepressant patent?

Historical patents may have covered the compound, formulations, treatment methods, or manufacturing processes. Those rights did not support a marketed product or an Orange Book exclusivity period.

Could edivoxetine return to the market?

A return is theoretically possible through licensing or acquisition, but it would require a new sponsor to address the prior efficacy failure and establish a viable regulatory and commercial strategy.

References

  1. Eli Lilly and Company. (2014). 2013 annual report. Indianapolis, IN: Author.

  2. National Library of Medicine. (2024). ClinicalTrials.gov: Studies involving edivoxetine (LY2216684) in major depressive disorder. U.S. National Library of Medicine. https://clinicaltrials.gov/

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.